Jardiance's Win in HFpEF; ECGs in Prone Position; Progress on 'Universal' Stem Cells

(MedPage Today) -- Treatment with empagliflozin (Jardiance) led to reductions in cardiovascular events for people with heart failure with preserved ejection fraction (HFpEF), EMPEROR-Preserved investigators announced. Detailed results will be presented...